Are peptides legal in the UK?

Some are and some aren't, and for most peptides the answer depends less on the molecule than on how it is sold.

• Most peptides are not controlled drugs. The exceptions that matter in this market are human growth hormone (somatropin) and chorionic gonadotrophin (HCG), which are Class C under the Misuse of Drugs Act 1971.
• Any peptide can be a medicine in the eyes of the law. It is one if it is presented as treating or preventing disease, or if it is used to change how the body works. Selling, supplying or advertising a medicine that has no UK authorisation is an offence.
• A "research use only" label doesn't change that. The medicines regulator, the MHRA, has said it disregards research claims when they are used to get round the medicines rules.
• Retatrutide has no UK authorisation. The MHRA says anyone selling it is doing so illegally.
• Some peptides are perfectly ordinary. Peptides in properly notified skincare products, collagen peptides sold as food, and licensed peptide medicines supplied on prescription are all legal, each under its own rules.

The rest of this page explains how those rules work, with the regulator's own words and dates. If the chemistry is new to you, What is a peptide? covers the basics.

1. Is it a controlled drug?

The Misuse of Drugs Act 1971 names controlled drugs one by one. Most peptides sold in the UK are not on the list. Schedule 2, Part III of the Act (Class C) does include chorionic gonadotrophin (HCG), non-human chorionic gonadotrophin, somatotropin, somatrem and somatropin (forms of human growth hormone). Controlled drugs have their own, stricter regime: GOV.UK's guidance on importing medicines says that if a medicine contains a controlled substance, "you must contact the Home Office".

2. Is it a medicine?

This is the question that catches most people out. The Human Medicines Regulations 2012 define a medicinal product in two parts. As quoted in the MHRA's guidance (Guidance Note 8, May 2026), a product is a medicine if it is:

"Any substance or combination of substances presented as having properties for treating or preventing disease in human beings"

or

"Any substance or combination of substances which may be used in, or administered to, human beings, either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis"

The first part is about presentation: what the seller says or implies the product does. The second is about function: what the product does in the body. Either one is enough. "Disease" is wide, too: the regulations define it as including "any injury, ailment or adverse condition, whether of body or mind".

The MHRA decides whether a product is a medicine case by case. Once something is a medicine, it needs a UK authorisation before it can be sold, and the MHRA's guidance states plainly: "It is an offence to sell or supply or to advertise a medicinal product which does not have authorisation."

Guidance Note 8 lists what the regulator weighs when it judges how a product is presented. In its words:

• "all claims made for the product, both explicit and implicit, including any made on websites, linked helplines, testimonials, linked publications, or in social media. Implicit claims may include product names"
• "the context in which the claims are made, and the overall presentation"
• "the labelling and packaging/package inserts including any graphics"
• "the product form, (capsule, tablet, injection etc.) and the way it is to be used"
• "any particular target of the marketing information/advertising material"

Its appendix on selling online goes further. "If you are using the internet to sell products that are not medicines, you should ensure that your entire website or social media content is free of all direct and implied medicinal claims." The examples it gives include information about the medicinal uses of an ingredient, "even if they do not directly relate to the product in question"; lists of medical conditions that lead to a product; "Publication of third-party articles, reports, clinical data, medical research or newspaper articles"; blogs and videos about medicinal use; customer reviews that mention medicinal use; and before-and-after pictures.

Put simply: a vial of powder sold next to a dosage chart, a suggested "stack" and reviews about recovery is being presented as a medicine, whatever the label on the box says.

Genuine research supply is real and lawful. Universities, research institutes and companies buy research-grade peptides for laboratory work every day. What makes it research supply is who buys it, what they buy it for, and how it is presented, not the words on the sticker.

The regulator has been direct about the difference. In March 2026 the MHRA's head of borderlines, Lynda Scammell, told STV News: "We disregard claims that products are for 'research purposes'" where they are used to get round the medicines rules. In the same report the Department of Health and Social Care said: "The MHRA will take action to remove any products disingenuously advertised as 'research only'."

Product form counts as well. In a 2024 freedom of information answer about Melanotan II, the MHRA said products containing it are classified as medicines if they are injectable or pens.

We explain what the label does and doesn't mean in more detail in Research use only, explained.

Importing medicines into the UK needs licences too. For unlicensed medicines, GOV.UK's guidance says an importer needs a manufacturer's "specials" licence or a wholesale dealer's licence, depending on the country, and must notify the MHRA first: "You can only proceed with the import if the MHRA does not object to it."

Regulation 279 of the Human Medicines Regulations says: "A person may not publish an advertisement in Great Britain for a medicinal product" unless it holds a UK authorisation. An advertisement covers "any published materials or any other activities which are designed to promote the prescription, supply, sale or use of medicines by the general public", which includes websites and social media.

For licensed prescription medicines, the MHRA's Blue Guide is just as clear: "the promotion of prescription only medicines to the public using the internet or other digital channels is prohibited." Its guidance for clinics and other providers adds that "Unlicensed medicines should not be mentioned" in their promotion, and that treatments using unlicensed medicines "may not be described as 'clinically proven' or similar."

The Advertising Standards Authority enforces the same line. In February 2026 it ruled against a series of Instagram and TikTok adverts for weight-loss injections, and treated even the term "GLP-1" as a reference to a class of prescription-only medicines.

Retatrutide is still in clinical development and has no UK authorisation. On 24 July 2026 the MHRA said: "It has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally." It added that such products "haven't been tested for safety, quality or effectiveness" and that "there's no guarantee that they even contain retatrutide."

The enforcement has been real. On 28 May 2026 the MHRA raided a site it believed was making "unlicensed weight loss medicines, including retatrutide and tirzepatide, as well as peptide products", and two men were arrested on suspicion of offences under the Human Medicines Regulations. On 14 October 2026 the MHRA and West Midlands Police seized "over 12,000 fake retatrutide and tirzepatide pens" in Birmingham, worth about £2 million. The regulator's statement was blunt: "Products being sold as retatrutide outside legitimate clinical trials are being supplied illegally."

The licensed weight-loss medicines, such as semaglutide and tirzepatide products, are prescription-only. The government's guidance on GLP-1 medicines explains how to get them safely.

We do not supply retatrutide in the UK, or any other weight-loss research peptide.

In April 2026 the Guardian reported that the MHRA would investigate UK peptide clinics over the health claims they make. The rules above apply to clinics as much as to online sellers: an unlicensed medicine can't be advertised to the public, and a treatment that relies on one can't be sold as "clinically proven".

The direction is towards less tolerance, not more.

For medicines, the government's advice is to buy only from a registered pharmacy with a valid prescription where one is needed. GOV.UK has a service to check a suspicious online seller of medicines, and the MHRA's #FakeMeds campaign explains what to look for: fakemeds.campaign.gov.uk.

For research materials, a legitimate supplier should be easy to verify:

• a company you can find on a public company register (in the UK, Companies House), with the same name and address as on its website;
• a certificate of analysis for the exact batch it supplies;
• named people you can contact;
• a buyer check before it supplies research-grade products, and no dosing or usage advice, ever.

We supply businesses and institutions, not individuals. Research-grade products go only to research buyers we have verified, with a signed end-use declaration, and we never describe them in terms of what they might do in a body. Licensed medicines go only to licensed buyers, as the registered product. Cosmetic ingredients go to skincare businesses for topical products. You can read exactly who qualifies in research buyer verification, and how licensed supply works in licensed medicines.

• MHRA, Guidance Note 8: A guide to what is a medicinal product (12 May 2026)
• MHRA, The Blue Guide: Advertising and Promotion of Medicines in the UK, sections 5.10 and 6.3, and Appendix 6
• Misuse of Drugs Act 1971, Schedule 2
• MHRA, freedom of information response FOI 24/274 on Melanotan II
• STV News, "The peptide boom", 19 March 2026
• MHRA news releases of 29 May, 24 July and 15 October 2026
• GOV.UK, Import a human medicine (updated 29 January 2025)
• GOV.UK, Making cosmetic products available to consumers in Great Britain
• Advertising Standards Authority rulings of 11 February 2026
• The Guardian, 4 April 2026
• GOV.UK, Psychoactive Substances Act 2016: guidance for researchers
• GOV.UK, GLP-1 medicines for weight loss and diabetes: what you need to know

• 9 November 2026: reviewed by our lawyer.
• 8 November 2026: first written.